Surrozen, Inc. (SRZN): Total Assets
$98.73M
As of 2025-12-31
$115.61M
As of 2026-06-30
+3.3%
3-year compound annual growth
+9.7%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $98.73M | +103.7% | 2026-03-23, Balance as of period end |
| 2024-12-31 | $48.47M | +5.2% | 2026-03-23, Balance as of period end |
| 2023-12-31 | $46.08M | -48.5% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $89.44M | -34.8% | 2024-04-10, Balance as of period end |
| 2021-12-31 | $137.17M | +121.0% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $62.06M | n/a | 2022-03-28, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Surrozen, Inc. (SRZN) | 2025-12-31 | $98.73M | +103.7% |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $2.27B | +1.0% |
| Dyadic International Inc (DYAI) | 2025-12-31 | $9.95M | +0.2% |
| CG Oncology, Inc. (CGON) | 2025-12-31 | $791.59M | +4.9% |
| Ocugen, Inc. (OCGN) | 2025-12-31 | $43.52M | -47.2% |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | $342.73M | +15.2% |
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | $1.53M | -7.1% |
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | $88.53M | +26.3% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $233.72M | +256.0% |
Compare SRZN, CRSP, DYAI, CGON side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗